Retinoblastoma Treatment in India — Leading Paediatric Eye Cancer Care
Retinoblastoma treatment in India from $4,000. Chemotherapy, laser, cryotherapy & globe-saving surgery by India's top paediatric oncologists. 96% survival rate. Consult GAF Healthcare today.
Estimated cost: $4,000 – $12,000 · Average stay: 7–14 days
Retinoblastoma is the most common intraocular malignancy in children, arising from immature retinal cells. It occurs in approximately 1 in 15,000–20,000 live births and accounts for 3% of all childhood cancers. The majority of cases present before the age of five; bilateral (both eyes) disease almost always has a genetic basis (germline RB1 gene mutation) and has a median age of diagnosis of 12 months, while unilateral disease is usually sporadic and presents at around 24 months.
India has the world's highest burden of retinoblastoma — approximately 1,500 new cases per year — but it has also developed, out of necessity, some of the world's most experienced and innovative retinoblastoma treatment centres. Sankara Nethralaya's Dr. Vikas Khetan leads one of Asia's busiest retinoblastoma programmes; LV Prasad Eye Institute, Aravind Eye Hospital, and Tata Memorial Hospital (Mumbai) are other major centres. India's retinoblastoma specialists have pioneered intra-arterial chemotherapy (chemosurgery) and intravitreal chemotherapy delivery techniques that are now used globally.
For international families seeking specialist retinoblastoma care — particularly from the UAE, Africa, and South Asia — India offers world-class, globe-saving treatment at 60–80% below equivalent costs in the USA or UK, with English-speaking medical teams experienced in coordinating care with families who have travelled from abroad.
Understanding Retinoblastoma
Retinoblastoma arises when cells in the developing retina accumulate mutations in both copies of the RB1 tumour suppressor gene. In hereditary (germline) retinoblastoma, one RB1 mutation is present in every cell of the body from conception; only a second somatic mutation is required for a retinal cell to become malignant, explaining the earlier age of onset, bilateral disease, multifocal tumours within each eye, and the increased lifetime risk of secondary cancers in other tissues (particularly osteosarcoma and soft tissue sarcomas in adolescence and adulthood).
The classic presenting sign is leukocoria — a white pupillary reflex (white instead of the normal red reflex) visible in photographs or in direct light, often first noticed by parents. Squint (strabismus), reduced vision (in older children), red painful eye (in advanced disease), and proptosis (in extraocular extension) are other presentations. Any child with leukocoria must be evaluated by an ophthalmologist as an emergency.
Tumours are classified by the International Classification of Retinoblastoma (ICRB) as groups A through E, from very small tumours with excellent prognosis (Group A) to extensive disease with vitreous or subretinal seeding (Group E). Group A–C tumours have excellent globe salvage rates with contemporary focal and systemic therapy; Group D and E eyes have lower globe salvage rates, and Group E eyes in developed care systems are often primarily enucleated (removed) in the child's best interests. Extraocular extension (spread to the optic nerve beyond the lamina cribrosa, choroid, or orbit) significantly worsens the systemic prognosis and requires adjuvant systemic chemotherapy and sometimes external beam radiotherapy.
Who Needs Retinoblastoma Treatment?
Every child diagnosed with retinoblastoma — whether unilateral or bilateral — requires urgent treatment. There is no watchful waiting for retinoblastoma. The goals of treatment, in order of priority, are: saving the child's life, preserving the eye, and maximising the useful vision.
All siblings and parents of a child with bilateral retinoblastoma or with a family history of retinoblastoma should undergo genetic testing for RB1 mutations and regular dilated retinal examination under anaesthesia (EUA) until the age of 5. Unaffected carriers of germline RB1 mutations require lifelong cancer surveillance as they have an elevated risk of secondary malignancies.
India's retinoblastoma centres offer rapid genetic counselling and RB1 germline testing as part of the diagnostic work-up, as the result fundamentally affects both the treatment plan for the affected child and the surveillance protocol for the family.
Treatment Approaches for Retinoblastoma
Treatment is highly individualised based on tumour classification (ICRB group), laterality (unilateral vs bilateral), the child's systemic health, and the family's wishes. The major treatment modalities, used alone or in combination, are:
Systemic Chemotherapy (intravenous chemoreduction) using carboplatin, vincristine, and etoposide (the standard CEV regimen) shrinks tumours sufficiently to allow focal consolidation therapy. It is the standard initial treatment for group C–D bilateral tumours and as adjuvant therapy for extraocular disease. Six cycles are delivered over approximately six months; each cycle requires a short hospital admission.
Intra-arterial Chemotherapy (IAC, chemosurgery) delivers high concentrations of melphalan (and sometimes topotecan or carboplatin) directly into the ophthalmic artery via a microcatheter threaded from the femoral artery under fluoroscopic guidance. IAC has revolutionised globe salvage rates for group D and selected group E eyes that previously required enucleation, achieving globe salvage in 70–80% of eyes that would otherwise have been removed. India's IAC programmes at Sankara Nethralaya and LV Prasad Eye Institute are among the most experienced in Asia.
Intravitreal Chemotherapy (IViC) delivers melphalan or topotecan directly into the vitreous through a fine needle under strict antiseptic conditions, specifically targeting vitreous seeds (free-floating tumour cells in the vitreous gel) that cannot be reached by systemic or intra-arterial routes. Multiple injections are given at 3–4 week intervals.
Focal Consolidation — laser photocoagulation (to seal feeding vessels and directly ablate small tumours), thermotherapy (diode laser hyperthermia), and cryotherapy (freezing treatment applied via a cryoprobe through the sclera) — is used to treat residual or focal tumours after chemoreduction and as primary treatment for small (Group A–B) tumours.
Enucleation (surgical removal of the eye) remains necessary for Group E eyes that are blind and painful, have no useful vision, or have failed all globe-salvage treatments, and for eyes with optic nerve or choroidal invasion on histology. Enucleation with prosthetic implant provides an excellent cosmetic outcome, and the socket can be fitted with a custom ocular prosthesis (artificial eye) within weeks.
External beam radiotherapy (EBRT) is now used much less than in the past due to its association with secondary cancers (particularly sarcomas) in the radiation field in children with germline RB1 mutations. It is reserved for salvage of eyes that have failed all other treatments and for orbital recurrence after enucleation.
Procedure Steps
- Examination under anaesthesia (EUA) with wide-field RetCam fundus photography and RetCam fluorescein angiography to map all tumours
- MRI of brain and orbits with gadolinium contrast to exclude extraocular extension and pinealblastoma (trilateral retinoblastoma)
- Systemic work-up including bone marrow aspirate, lumbar puncture, and bone scan in advanced or extraocular cases
- RB1 germline genetic testing from peripheral blood
- Multidisciplinary team discussion (ophthalmologist, paediatric oncologist, radiation oncologist, geneticist)
- Chemotherapy cycles (systemic, intra-arterial, or intravitreal) administered under monitored protocols
- Focal consolidation (laser/cryo/thermotherapy) at each EUA to treat residual tumour
- Regular EUAs every 4–6 weeks during active treatment; 3-monthly when in remission; 6-monthly thereafter until age 5
Cost Comparison Worldwide
Country — Range — Savings
--- — --- — ---
USA — $80,000 – $200,000 — Save up to 90%
UK — £30,000 – £80,000 — Save up to 85%
Singapore — $40,000 – $90,000 — Save up to 82%
UAE — $30,000 – $70,000 — Save up to 80%
India — $4,000 – $12,000 — Best value
Retinoblastoma treatment in the USA can cost $80,000–$200,000 for a full course of intravenous chemotherapy, intra-arterial chemotherapy, and focal treatments combined. In the UK, NHS treatment is available but waiting times can be prolonged for international families seeking a second opinion or for patients who are not UK residents. In India, the same evidence-based protocols — including systemic CEV chemotherapy, intra-arterial chemotherapy with melphalan, intravitreal injections, and all focal consolidation procedures — cost between $4,000 and $12,000 for a complete treatment course.
India's leading retinoblastoma centres receive significant institutional and charitable funding that keeps costs accessible, while their private-rate tariffs for international patients still represent major savings over equivalent Western care. GAF Healthcare provides itemised cost estimates before the patient's family commits to travelling, and can coordinate phased payment schedules for multi-cycle treatment programmes. We work with the child's home oncology team to facilitate data sharing and to plan chemotherapy cycles that can be partially delivered in the home country, minimising the family's total time in India.
Recovery & Follow-up
Recovery from individual treatment sessions (EUAs, chemotherapy cycles, IAC procedures) is typically rapid. Children generally recover from general anaesthesia within hours. Chemotherapy side effects — fatigue, nausea, hair loss — peak a few days after each cycle and resolve by the time the next cycle is due. IAC is well tolerated and has fewer systemic side effects than intravenous chemotherapy, though the access procedure carries small risks of vascular complications.
Long-term surveillance is the most important aspect of retinoblastoma aftercare. Children with germline RB1 mutations require regular EUAs until age 5, then annual retinal examinations and annual MRI (or PET-CT in some protocols) until adulthood, plus surveillance for secondary cancers throughout life. Children with unilateral, non-hereditary retinoblastoma have a much lower risk of secondary tumours and require regular eye examinations in the treated eye plus monitoring of the fellow eye until age 5.
Visual outcomes depend on tumour location, size, and response to treatment. Tumours not involving the fovea (centre of the macula) carry an excellent visual prognosis. Foveal tumours almost always result in significant central vision loss in the affected eye regardless of treatment modality.
Recovery Tips
- Keep all scheduled examination under anaesthesia (EUA) appointments — these are how the team confirms tumour control
- Report immediately any new leukocoria, redness, or change in the eye's appearance between scheduled visits
- Ensure siblings and parents have completed RB1 genetic testing and retinal screening
- Keep a medication record and chemotherapy cycle schedule — GAF Healthcare provides a patient-held health record for international families
- Maintain dental hygiene carefully during chemotherapy — mouth sores and infection risk are increased
- Ensure the child wears UV-blocking sunglasses outdoors, especially if radiotherapy was part of treatment
- Register with a local paediatric ophthalmologist for ongoing surveillance at home between India visits
Risks & Complications
The risks of retinoblastoma treatment must be weighed against the risks of untreated disease, which is uniformly fatal. Systemic chemotherapy risks include myelosuppression (low blood counts increasing infection risk), ototoxicity from carboplatin (hearing loss, usually mild), nephrotoxicity, and a small increased risk of secondary leukaemia from etoposide. Intra-arterial chemotherapy risks include vasospasm, retinal artery occlusion (rare), and local orbital/retinal toxicity. Intravitreal injections carry a very small risk of infection (endophthalmitis) and vitreous haemorrhage.
Enucleation results in permanent loss of the eye, though prosthetic eyes are cosmetically excellent and orbital growth is usually adequate. Children with germline RB1 mutations have a cumulative 20% lifetime risk of secondary cancers; the most common are osteosarcoma, soft tissue sarcomas, and melanoma. Radiotherapy significantly increases this secondary cancer risk and is therefore avoided unless there is no alternative.
India's leading retinoblastoma programmes have safety protocols that meet or exceed international standards. Treatment decisions are made in multidisciplinary team meetings, and outcome data are prospectively collected and reviewed. Families can request the centre's published outcome data before committing to treatment.
Why GAF Healthcare
Retinoblastoma demands subspecialist expertise that is rare even in developed countries. GAF Healthcare connects international families exclusively with India's highest-volume, most experienced retinoblastoma programmes — centres whose specialists are internationally recognised, speak fluent English, and have experience managing the practical and emotional needs of families who have travelled from abroad in crisis.
Our coordinators provide a dedicated point of contact from the moment of first enquiry. We expedite emergency medical visa applications, arrange family accommodation close to the hospital, coordinate with the home paediatric team, and provide translated copies of all reports for the family's home country doctors. We also offer ongoing support between India visits, including teleconferencing with the treating team when families are back home. Nobody should have to navigate a childhood cancer diagnosis alone, and GAF Healthcare ensures they do not have to.
Frequently Asked Questions
Is retinoblastoma curable?
Yes. With appropriate modern treatment, the survival rate for retinoblastoma is over 96% in India's leading centres (and up to 99% in some early-stage series from high-income countries). The overall cure rate for life is excellent. The challenge is preserving the eye and useful vision alongside curing the cancer — India's specialist programmes achieve globe salvage in 70–85% of eyes referred for treatment, depending on the stage at presentation.
Does my child need to stay in India for the entire treatment course?
Not necessarily. GAF Healthcare works with families to design a treatment schedule that minimises total time in India. Systemic chemotherapy cycles can sometimes be partially administered by the child's home oncologist (with data shared between teams). However, intra-arterial chemotherapy, intravitreal injections, and examination under anaesthesia must be performed at the specialist centre. A typical schedule involves 3–4 visits to India, each of 5–10 days, over a 6–9 month period.
What is the white reflex (leukocoria) in my child's eye and should I be concerned?
Leukocoria — a white glow in the pupil, often first noticed in flash photographs — is the most common presenting sign of retinoblastoma and demands urgent ophthalmic evaluation, ideally within 24–48 hours. Other causes of leukocoria exist (including cataract, persistent fetal vasculature, Coats disease, and toxocariasis), but retinoblastoma must be excluded first. If you notice a white reflex in your child's eye, contact GAF Healthcare for an emergency consultation referral immediately.
Should siblings and parents be tested for retinoblastoma?
Yes, in all cases where retinoblastoma is bilateral, multifocal, or diagnosed at a young age (under 12 months), and in all cases where there is a family history of retinoblastoma. Siblings and parents should undergo RB1 germline genetic testing and, if the family mutation is identified, dilated retinal examination every 3–4 months until age 5. Even without genetic testing, all siblings of a retinoblastoma patient should have a retinal examination by a specialist.
What if my child needs an artificial eye (ocular prosthesis) after enucleation?
Enucleation (eye removal) is performed with insertion of a spherical orbital implant to maintain orbital volume and support the eyelids. An ocular prosthesis (artificial eye) custom-painted to match the fellow eye is fitted by an ocularist (prosthesis specialist) approximately 4–6 weeks after surgery. India has excellent ocularists at all major centres and GAF Healthcare can arrange this fitting as part of the care package. The cosmetic result is very good, particularly in young children whose orbits continue to grow around the implant.